Federal Circuit Establishes New Standard for Inequitable Conduct

On May 25, 2011 the Federal Circuit released its en banc decision in Theresense, Inc. v. Becton, Dickinson & Co. , in which the Court articulated the appropriate standard for inequitable conduct before the PTO.  The majority wrote, “[t]his court now tightens the standards for finding both intent and materiality in order to redirect a doctrine that has been overused to the detriment of the public.”  

Majority

At issue in the district court was the 5,820,551 patent which involved disposable blood glucose test strips for diabetes management.  Protective membranes are often used on such glucose test strips to protect the veracity of the results.  The ‘551 patent disclosed a test unit without a protective membrane.  The Examiner cited the 4,545,382 patent, also held by Abbott, as disclosing a unit which could be used without a membrane.  A declaration and affidavit was submitted explaining the language of the ‘382 patent would not encourage one of ordinary skill in the art to use the device without a membrane, and the Examiner relied upon the statements for allowance of the ‘551 patent.  It came to light during litigation that Abbott had previously made representations to the European Patent Office that, in fact, “[the] disclosure was unequivocally clear:” the membrane of the ‘382 patent was optional.  At the district court level, claims 1–4 of the ‘551 patent were held invalid as obvious and the ‘551 patent was held unenforceable due to inequitable conduct.  

The majority undertook a discussion of the Keystone, Hazel-Atlas, and Precision cases which set forth the test for unclean hands, the precursor to inequitable conduct.  The Court continued, discussing the ways in which the inequitable conduct doctrine diverged from these original cases, expanding to include a broader scope of misconduct—“mere non-disclosure” to the PTO—and by adopting a more potent remedy—unenforceability of the entire patent.  This lead to the sliding scale test, the “reasonable examiner standard” and the standards articulated in 37 C.F.R. 1.56.

The Court continued, noting that these standards lack uniformity and encourage the use of the “atomic bomb” of patent law.  “Left unfettered, the inequitable conduct doctrine has plagued not only the courts but also the entire patent system.”  The Court then proceeded to “tighten the standard.”  For purposes of the intent prong, the Court held, “the accused infringer must show the patentee acted with the specific intent to deceive the PTO.”  This requires “clear and convincing evidence must show that the applicant made a deliberate decision to withhold a known material reference.”  No longer will the “should have known” analysis satisfy this standard.   Finally, the absence of a good faith explanation does not, by itself, prove the intent to deceive.  With respect to the materiality prong, the Court articulated a “but for” materiality standard.  Thus, “when an applicant fails to disclose prior art to the PTO, that prior art is but-for material if the PTO would not have allowed a claim had it been aware of the undisclosed prior art.”  Important to note, the decision articulates a preponderance of the evidence standard for the “but for” test, which is different than the clear and convincing evidence standard required for invalidity.  Finally the court notes an exception to the “but for” test—in cases of “affirmative egregious misconduct,” the materiality prong may also be satisfied.  The Court vacated the finding of materiality at the district court and remanded for application of the new test:

1.    Intent:  clear and convincing evidence must show that the applicant made a deliberate decision to withhold a known material reference.
2.    Materiality:  preponderance of the evidence must show that the PTO would not have allowed a claim had it been aware of the undisclosed prior art—“but for” test.
a.    Exception:  affirmative egregious misconduct.

Concurrence

    The concurring opinion criticizes both the majority and the dissent for as sacrificing flexibility for rigidity.  The concurrence agrees with the majorities overall holding, but wishes to respect the equitable nature of the test.  This means leaving the decision of inequitable conduct to the decision of the lower courts.  The opinion notes this would help in the instance there is some intentional misconduct which does not fit within the rigid test, yet still warrants equitable relief.  This includes allowing the district court to “fashion some other reasonable remedy, so long as the remedy imposed by the court is ‘commensurate with the violation.’”  The concurrence articulates a materiality test including:

1.    But for the conduct (whether it be in the form of affirmative act or intentional non-disclosure), the patent would not have issued (as Chief Judge Rader explains in the majority opinion);
2.    The conduct constitutes a false or misleading representation of fact (rendered so either because the statement made is false on its face or information is omitted which, if known, would render the representation false or misleading); or
3.    The district court finds that the behavior is so offensive that the court is left with a firm conviction that the integrity of the PTO process as to the application at issue was wholly undermined.

Dissent

    The dissent begins by noting that the “specific intent,” as articulated by the majority and the clear and convincing evidence standard.  The disagreement revolves around the materiality standard.  The dissent would prefer to continue to apply the standard as articulated in 37 C.F.R. 1.56 because “[f]irst, examiners need to conduct effective and efficient examinations, i.e., what information is material to the examination process.  Second, the higher standard of materiality adopted by the majority will not provide appropriate incentives for patent applicants to comply with the disclosure obligation the PTO places on them.”  Essentially, the dissent would re-affirm the standard articulated in Kingsdown Medical.  The test from the dissent would require:

1.    Inequitable conduct requires proof, by clear and convincing evidence, that the applicant or attorney intended to misled the PTO with respect to the material matter.
2.    Materiality is measured by what the PTO demands of those who apply for and prosecute patent applications.  The disclosure standard for the PTO expects those parties to comply with is set forth in the current version of the PTO’s Rule 56.  Under that standard, inequitable conduct requires proof that the information at issue either established, by itself or in combination with other information, a prima facie case of unpatentability, or was inconsistent with a position taken by the applicant before the PTO with respect to patentability.
3.    Intent to mislead and materiality must be separately proved.  There is no “sliding scale” under which the degree of intent that must be proved depends on the strength of the showing as to the materiality of the information at issue.

The dissent continues, describing the veracity of such a test for policy reasons and for reasons of deference to the PTO.  Further, the dissent articulates this standard as more historically accurate with the  Keystone, Hazel-Atlas, and Precision cases.  The dissent describes the majority test as “Draconian” and inappropriate within the context of history, precedent, and the public policy consideration of the inequitable conduct doctrine.

For the full opinion, click here .

Federal Circuit requires agency relationship or contractual obligation for joint infringement

To establish infringement of a method claim, a patent holder must show that all of the recited steps in the claim are performed by a defendant.  If the recited steps are not performed by a single entity, but by the defendant acting in concert with another party, the patent holder may still show “joint infringement” if the defendant controls or directs the activities of another party.

In Akamai Technologies v. Limelight Networks, the Federal Circuit looked at what types of activities qualify as directing or controlling the activity of a another party.  The court opted for a bright-line rule that requires either a principal-agent relationship or a contractual obligation to perform the steps of the claim.

More details of Akamai Techs. v. Limelight Networks after the jump.

[More]

Federal Circuit determines that method for optimizing dosing of medication is patent eligible

The Federal Circuit on Friday looked at the issue of what constitutes an attempt to patent a natural phenomenon.   In Prometheus Laboratories, Inc. v. Mayo Collaborative Services, the Federal Circuit determined that a method for optimizing the dosage of a medication was not directed to a natural phenomenon and therefore was patent-eligible subject matter within the meaning of § 101 of the Patent Act. This is the second case in as many weeks refining the analysis of patent-eligible subject matter in light of this summer's Supreme Court ruling in Bilski v. Kappos.

More details of Prometheus Labs., Inc. v. Mayo Collaborative Servs. after the jump.

Inventor's prior art patents and prosecution history lead to reversal of claim construction

In a recent decision, the Federal Circuit reversed a district court's grant of summary judgment of noninfringement and invalidity based on inadequate written description.  The issue of infringement was reversed based on the district court's incorrect construction of a critical claim limitation.  While the court held it was a "close case," it held the patentee had not acted as his own lexicographer and the specification and file history showed a broader construction was appropriate.  In addition, a broader construction was supported by usage of the term in prior art patents by the same inventor.

On the written description issue, the court held there was at least a factual issue as to whether limitation at issue, which permitted reinforcement of any portion of a portion of the claimed product, was inadequately described.  The court observed that the allegedly limiting language was a "preferred aspect" of the invention, and thus the patentee's experts' testimony that one in the art would interpret the specification as more broadly disclosing the device was sufficient to generate a fact issue.  The district court characterized this testimony as "not helpful" when granting summary judgment of invalidity. 

More detail of Laryngeal Mask Co. v. Ambu A/S after the jump.
 

Compliance with industry standards can be used to show patent infringement

In Fujitsu et al v. Netgear, the Federal Circuit held compliance with an industry standard can be sufficient evidence to establish patent infringement.  However, this rule only applies when the only way to adhere to the industry standard is to infringe the asserted patent, such that any product that complies with the standard infringes.  In this case, the court determined that a party could comply with the standards at issue without infringing the patents; therefore, direct comparison of the products with the claims was necessary.

More detail after the jump.

[More]

Federal Circuit decisions address false marking statute in Solo Cup and Brooks Brothers cases

The Federal Circuit continues to address false marking cases. The court's recent decisions stress how important it is for patentees to monitor and update their labeling and other marking activities, particularly as patents expire.

In June, the court affirmed a summary judgment decision in favor of Solo Cup related to the company's practice of marking patents on beverage cup lids, and addressed whether each decision to mark or each article falsely marked is an act of false marking under the statute.  In August, the court addressed the issue of who has standing to bring a false marking case, reversing a district court's finding of lack of standing in a false marking case brought against Brooks Brothers. 

The Solo Cup case demonstrates the potential damage awards against companies that sell numerous products can be very large.  However, the court created a higher bar for plaintiffs seeking to cash in on the false marking statute and demonstrates the importance for a defendant to be able to show good faith actions to overcome any presumption of intent to deceive the public.

The Brooks Brothers case provides a lesson on standing under 35 U.S.C. § 292.   The Federal Circuit held a plaintiff has standing as a result of sufficiently alleging an injury in fact to the U.S. that was caused by Brooks Brothers' false marking of its bow ties, that may be redressed with the statutory fine created by § 292.  This removes a potential barrier to false marking suits being filed in the first instance.

More detail of these two cases after the jump.

[More]

Preamble held not limiting because body of claim sets forth complete invention

In a recent decision, the Federal Circuit reversed a decision of the United States District Court for the District of Massachusetts. The district court had granted summary judgment of noninfringement to the defendant finding that the defendant's accused device did not perform a function found only in the preambles of the asserted claims.

The Federal Circuit held that the disputed preamble term did not limit the asserted claims, and therefore, reversed and remanded the case for further findings.  Specifically, the court noted there was no suggestion in the prosecution history that the preamble was limiting, the preamble did not provide any antecedent basis for terms in the body of the claim (even though one element used "the" in the body of the claim), and the preamble did not define an essential component of the invention, such that the body of the claim defined the complete invention.  Based on these factors, the preamble was not a limitation of the claim, and the summary judgment of noninfringement was reversed.

Judge Dyk dissented, and invited the court to take the issue of preambles en banc to create a bright-line rule that preambles are always limiting, rather than relying on the context of each patent.

More concerning Am. Med. Sys., Inc. v. Biolitec, Inc. after the jump.

[More]

Another issue headed for en banc review by the Federal Circuit: How to assess redesigned products

In an order Friday, the Federal Circuit granted en banc review of its second case in the past three weeks and its third over the past three months.  This time it's a case involving Tivo relating to the contempt proceedings against Echostar relating to Tivo's DVR patents.  After Echostar was found to infringe Tivo's patent and was permanently enjoined from infringement, it redesigned its DVR software.  Tivo asked the district court to hold Echostar in contempt for violating the injunction.  The district court agreed with Tivo, and the Federal Circuit affirmed.

That opinion has now been vacated, and the Federal Circuit has granted en banc review to address whether and in what circumstances a contempt proceeding is appropriate to address alleged infringement of a newly accused device.  Specifically, the questions presented are:

  1. Following a finding of infringement by an accused device at trial, under what circumstances is it proper for a district court to determine infringement by a newly accused device through contempt proceedings rather than through new infringement proceedings? What burden of proof is required to establish that a contempt proceeding is proper?
  2. How does “fair ground of doubt as to the wrongfulness of the defendant’s conduct” compare with the “more than colorable differences” or “substantial open issues of infringement” tests in evaluating the newly accused device against the adjudged infringing device? See Cal. Artificial Stone Paving Co. v. Molitor, 113 U.S. 609, 618 (1885); KSM Fastening Sys., Inc. v. H.A. Jones Co., 776 F.2d 1522, 1532 (Fed. Cir. 1985).
  3. Where a contempt proceeding is proper, (1) what burden of proof is on the patentee to show that the newly accused device infringes (see KSM, 776 F.2d at 1524) and (2) what weight should be given to the infringer’s efforts to design around the patent and its reasonable and good faith belief of noninfringement by the new device, for a finding of contempt?
  4. Is it proper for a district court to hold an enjoined party in contempt where there is a substantial question as to whether the injunction is ambiguous in scope? 

Consistent with its typical practice in en banc cases, the Federal Circuit is permitting amicus briefs on these issues.

To read the full order granting en banc review in Tivo, Inc. v. Echostar Corp., click here.

To read our post regarding the original appeal, click here.

Federal Circuit to consider overhaul of inequitable conduct standards en banc

In an order today, the Federal Circuit granted rehearing en banc in Therasense, Inc. v. Becton, Dickinson & Co.  The order indicates the court will be reconsidering its precedent on virtually the entire gamut of issues relating to inequitable conduct. Specifically, the questions presented are:

  1. Should the materiality-intent-balancing framework for inequitable conduct be modified or replaced?
  2. If so, how? In particular, should the standard be tied directly to fraud or unclean hands? See Precision Instrument Mfg. Co. v. Auto. Maint. Mach. Co., 324 U.S. 806 (1945); Hazel-Atlas Glass Co. v. Hartford-Empire Co., 322 U.S. 238 (1944), overruled on other grounds by Standard Oil Co. v. United States, 429 U.S. 17 (1976); Keystone Driller Co. v. Gen. Excavator Co., 290 U.S. 240 (1933). If so, what is the appropriate standard for fraud or unclean hands?
  3. What is the proper standard for materiality? What role should the United States Patent and Trademark Office's rules play in defining materiality? Should a finding of materiality require that but for the alleged misconduct, one or more claims would not have issued?
  4. Under what circumstances is it proper to infer intent from materiality? See Kingsdown Med. Consultants, Ltd. v. Hollister Inc., 863 F.2d 867 (Fed. Cir. 1988) (en banc).
  5. Should the balancing inquiry (balancing materiality and intent) be abandoned?
  6. Whether the standards for materiality and intent in other federal agency contexts or at common law shed light on the appropriate standards to be applied in the patent context.

The court explicitly allows for the filing of amicus briefs without leave of court, and also specifically invites the USPTO to file such a brief.

For the order granting rehearing en banc, click here.

For the original panel opinion (affirming the district court's finding of inequitable conduct), click here.

More detail of the original panel opinion after the jump.

[More]

En banc Federal Circuit reaffirms written description requirement is separate from enablement

Monday the Federal Circuit  released its en banc opinion in Ariad Pharmaceuticals, Inc. v. Eli Lily & Co., where the court addressed whether 35 U.S.C. § 112  has a written description requirement separate and apart from the enablement requirement.  A substantial majority of the court (10 judges) joined in the majority opinion, with two judges dissenting.  As summarized by the court:

We . . . read the statute to give effect to its language that the specification "shall contain a written description of the invention" and hold that § 112, first paragraph, contains two separate description requirements: a "written description [i] of the invention, and [ii] of the manner and process of making and using [the invention]."

The Federal Circuit analyzed several old Supreme Court cases, and concluded that the Supreme Court, while not specifically calling this requirement a "written description" requirement, has consistently held that an inventor must do more than simply enable one in the art to make and use the invention claimed, but also must describe what the invention is. 

This decision is not unexpected, and leaves intact the Federal Circuit's jurisprudence on the subject. In fact, one of the grounds for retaining the requirement is that forty years of case law has held such a requirement exists, and inventors have relied upon the requirement over the course of that time.  The court was reluctant to upset the settled expectations of the patent community.  The court also declined to set forth a rule where original claims always meet the written description requirement, noting:

Although many original claims will satisfy the written description requirement, certain claims may not. For example, a generic claim may define the boundaries of a vast genus of chemical compounds, and yet the question may still remain whether the specification, including original claim language, demonstrates that the applicant has invented species sufficient to support a claim to a genus. The problem is especially acute with genus claims that use functional language to define the boundaries of a claimed genus. In such a case, the functional claim may simply claim a desired result, and may do so without describing species that achieve that result. 

More detail of the en banc decision after the jump.  Click here for our post regarding the original panel decision, which has much of the factual background of the invention at issue.  Click here for a discussion of court's decision to grant en banc review, including the questions presented.

[More]

More Entries

BlogCFC was created by Raymond Camden. This blog is running version 5.8.001.